Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 24, 2022 22:41 ET | Source: Ascendis Pharma

Ascendis Pharma Prices US$500.0 Million Convertible Senior Notes Offering

COPENHAGEN, Denmark, March 24, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to create new product...
March 23, 2022 16:01 ET | Source: Ascendis Pharma

Ascendis Pharma Announces Proposed Convertible Senior Notes Offering

COPENHAGEN, Denmark, March 23, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to create new product...
March 13, 2022 17:53 ET | Source: Ascendis Pharma

Ascendis Pharma A/S Announces Phase 3 PaTHway Trial of TransCon™ PTH in Adults with Hypoparathyroidism Met Primary and All Key Secondary Endpoints

– For the primary composite endpoint, TransCon PTH demonstrated a response rate of 78.7% compared to 4.8% for control (p-value <0.0001). – TransCon PTH demonstrated statistically significant...
March 02, 2022 16:01 ET | Source: Ascendis Pharma

Ascendis Pharma A/S Reports Full Year 2021 Financial Results and Provides a Business Update

- Top-line results from PaTHway, a Phase 3 randomized study evaluating the safety, tolerability, and efficacy of TransCon™ PTH in adult hypoparathyroidism (HP) patients on track for this quarter -...
February 25, 2022 08:00 ET | Source: Ascendis Pharma

Ascendis Pharma A/S Announces Full Year 2021 Financial Results and Business Update Conference Call on March 2

COPENHAGEN, Denmark, Feb. 25, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company will hold a conference call and live webcast on Wednesday, March 2, 2022 at...
February 10, 2022 16:05 ET | Source: Ascendis Pharma

Ascendis Pharma A/S to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

COPENHAGEN, Denmark, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company is scheduled to participate in the 11th Annual SVB Leerink Global...
January 13, 2022 08:00 ET | Source: Ascendis Pharma

Ascendis Pharma A/S Receives European Approval for TransCon™ hGH for Pediatric Growth Hormone Deficiency

COPENHAGEN, Denmark, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the European Commission (EC) has granted marketing authorization for Lonapegsomatropin...
January 10, 2022 08:00 ET | Source: Ascendis Pharma

Ascendis Pharma A/S Provides Update on Vision 3x3 Strategic Roadmap at 40th Annual J.P. Morgan Healthcare Conference

COPENHAGEN, Denmark, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company will today provide an update on its Vision 3x3 and planned 2022 key...
January 04, 2022 08:00 ET | Source: Ascendis Pharma

Ascendis Pharma A/S to Participate in 40th Annual J.P. Morgan Healthcare Conference

COPENHAGEN, Denmark, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company is scheduled to participate in the upcoming 40th Annual J.P. Morgan...
December 14, 2021 08:00 ET | Source: Ascendis Pharma

Ascendis Pharma A/S Virtual R&D Program Update Highlights Continued Development Across R&D Pipeline

–– TransCon™ PTH Phase 3 topline results expected in Q1 2022 and, if positive, planned NDA submission in Q3 2022 followed by expected MAA submission in Q4 2022 –– Enrollment completed in Phase 2...